<?xml version='1.0' encoding='utf-8'?>
<document id="16958555"><sentence text="Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences."><entity charOffset="15-28" id="DDI-PubMed.16958555.s1.e0" text="buprenorphine" /></sentence><sentence text="Buprenorphine is an opioid agonist-antagonist with a 'ceiling effect' for respiratory depression"><entity charOffset="0-13" id="DDI-PubMed.16958555.s2.e0" text="Buprenorphine" /><entity charOffset="20-26" id="DDI-PubMed.16958555.s2.e1" text="opioid" /><pair ddi="false" e1="DDI-PubMed.16958555.s2.e0" e2="DDI-PubMed.16958555.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16958555.s2.e0" e2="DDI-PubMed.16958555.s2.e1" /></sentence><sentence text=" Compared with methadone, its unique pharmacology offers practical advantages and enhanced safety when prescribed as recommended and supervised by a physician"><entity charOffset="15-24" id="DDI-PubMed.16958555.s3.e0" text="methadone" /></sentence><sentence text=" Buprenorphine has been approved in several countries as an efficient and safe maintenance therapy for heroin addiction"><entity charOffset="1-14" id="DDI-PubMed.16958555.s4.e0" text="Buprenorphine" /></sentence><sentence text=" Its use resulted in a salutary effect with a reduction in heroin overdose-related deaths in countries that implemented office-based buprenorphine maintenance"><entity charOffset="133-146" id="DDI-PubMed.16958555.s5.e0" text="buprenorphine" /></sentence><sentence text=" In France, however, where high-dose buprenorphine has been marketed since 1996, several cases of asphyxic deaths were reported among addicts treated with buprenorphine"><entity charOffset="37-50" id="DDI-PubMed.16958555.s6.e0" text="buprenorphine" /><entity charOffset="155-168" id="DDI-PubMed.16958555.s6.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.16958555.s6.e0" e2="DDI-PubMed.16958555.s6.e0" /><pair ddi="false" e1="DDI-PubMed.16958555.s6.e0" e2="DDI-PubMed.16958555.s6.e1" /></sentence><sentence text=" Death resulted from buprenorphine intravenous misuse or concomitant sedative drug ingestion, such as benzodiazepines"><entity charOffset="21-34" id="DDI-PubMed.16958555.s7.e0" text="buprenorphine" /><entity charOffset="102-117" id="DDI-PubMed.16958555.s7.e1" text="benzodiazepines" /><pair ddi="false" e1="DDI-PubMed.16958555.s7.e0" e2="DDI-PubMed.16958555.s7.e0" /><pair ddi="false" e1="DDI-PubMed.16958555.s7.e0" e2="DDI-PubMed.16958555.s7.e1" /></sentence><sentence text=" In these situations of abuse, misuse, or in association with elevated doses of psychotropic drugs, buprenorphine may cause severe respiratory depression"><entity charOffset="100-113" id="DDI-PubMed.16958555.s8.e0" text="buprenorphine" /></sentence><sentence text=" Unlike other opiates, the respiratory effects from buprenorphine are not responsive to naloxone"><entity charOffset="52-65" id="DDI-PubMed.16958555.s9.e0" text="buprenorphine" /><entity charOffset="88-96" id="DDI-PubMed.16958555.s9.e1" text="naloxone" /><pair ddi="false" e1="DDI-PubMed.16958555.s9.e0" e2="DDI-PubMed.16958555.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16958555.s9.e0" e2="DDI-PubMed.16958555.s9.e1" /></sentence><sentence text=" However, the exact mechanism of buprenorphine-induced effects on ventilation is still unknown"><entity charOffset="33-46" id="DDI-PubMed.16958555.s10.e0" text="buprenorphine" /></sentence><sentence text=" The role of norbuprenorphine, the main N-dealkylated buprenorphine metabolite with potent respiratory depressor activity, also remains unclear"><entity charOffset="13-29" id="DDI-PubMed.16958555.s11.e0" text="norbuprenorphine" /><entity charOffset="54-67" id="DDI-PubMed.16958555.s11.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.16958555.s11.e0" e2="DDI-PubMed.16958555.s11.e0" /><pair ddi="false" e1="DDI-PubMed.16958555.s11.e0" e2="DDI-PubMed.16958555.s11.e1" /></sentence><sentence text=" Experimental studies investigating the respiratory effects of combinations of high doses of buprenorphine and benzodiazepines suggested that this drug-drug interaction may result from a pharmacodynamic interaction"><entity charOffset="93-106" id="DDI-PubMed.16958555.s12.e0" text="buprenorphine" /><entity charOffset="111-126" id="DDI-PubMed.16958555.s12.e1" text="benzodiazepines" /><pair ddi="false" e1="DDI-PubMed.16958555.s12.e0" e2="DDI-PubMed.16958555.s12.e0" /><pair ddi="false" e1="DDI-PubMed.16958555.s12.e0" e2="DDI-PubMed.16958555.s12.e1" /></sentence><sentence text=" A pharmacokinetic interaction between buprenorphine and flunitrazepam is also considered"><entity charOffset="39-52" id="DDI-PubMed.16958555.s13.e0" text="buprenorphine" /><entity charOffset="57-70" id="DDI-PubMed.16958555.s13.e1" text="flunitrazepam" /><pair ddi="false" e1="DDI-PubMed.16958555.s13.e0" e2="DDI-PubMed.16958555.s13.e0" /><pair ddi="false" e1="DDI-PubMed.16958555.s13.e0" e2="DDI-PubMed.16958555.s13.e1" /></sentence><sentence text=" As there are many questions regarding the possible dangers of death or respiratory depression associated with buprenorphine use, we aimed to present a comprehensive critical review of the published clinical and experimental studies on buprenorphine respiratory effects"><entity charOffset="111-124" id="DDI-PubMed.16958555.s14.e0" text="buprenorphine" /><entity charOffset="236-249" id="DDI-PubMed.16958555.s14.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.16958555.s14.e0" e2="DDI-PubMed.16958555.s14.e0" /><pair ddi="false" e1="DDI-PubMed.16958555.s14.e0" e2="DDI-PubMed.16958555.s14.e1" /></sentence><sentence text="" /></document>